Fundraising Fox

TC Biopharm

Holytown, Motherwell · 4 known investors

Developing a scalable off-the-shelf allogeneic gamma delta T cell therapy platform.

Founders & leadership

MT
Martin ThorpNamed on SEC filing
EN
Edward NiemczykNamed on SEC filing
MB
Mark BonyhadiNamed on SEC filing
ML
Michael LeekNamed on SEC filing
AM
Arlene MorrisNamed on SEC filing
JC
James CulverwellNamed on SEC filing
BK
Bryan KobelNamed on SEC filing

Investors · 4

Reported raises · per SEC filings

Form D private placements

$7.3M disclosed across 1 round · 2022

$7.3MraisedDec 2022 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Martin ThorpExecutive Officer, Director
  • Edward NiemczykDirector
  • Mark BonyhadiDirector
  • Michael LeekDirector
  • Arlene MorrisDirector
  • James CulverwellDirector
  • Bryan KobelDirector
Offering amount
$7.3M
Amount sold
$7.3M
Sales commissions
$551.3K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Nov 2022
Incorporated
Corporation, United Kingdom
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap

Companies competing with TC Biopharm for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does TC Biopharm do?
Developing a scalable off-the-shelf allogeneic gamma delta T cell therapy platform.
Who are TC Biopharm's investors?
TC Biopharm's investors include Investing Women Angels, NCL Technology Ventures Ltd., Crowdcube, Scottish Enterprise.
How much funding has TC Biopharm raised?
TC Biopharm has disclosed $7.3M raised across 1 round.
Where is TC Biopharm headquartered?
TC Biopharm is headquartered in Holytown, Motherwell.